A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07303803
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Registry
-
NCT07303803
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07303803. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2030-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
- Acronym
- CHIG-MASH
- Condition
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- Chiglitazar Placebo
- Intervention (Drug)
- Chiglitazar
- Intervention (Drug)
- vitamin E
- Intervention (Drug)
- Polyene Phosphatidyl choline
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Collaborator
- Chipscreen Biosciences, Ltd.
Record details
- Record id
cardio:ct-nct07303803- Content hash
a1c8234d10c8d22524688a4da53ae497d21f7e3f562923006efba2e41a6d2f0f